BeStock  
Markets › Compare › IMVT vs CYTK

IMVT vs CYTK

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
IMVT · Immunovant$31.77 ▼ 2.31%
CYTK · Cytokinetics$50.78 ▼ 1.32%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

69101134167200Nov 24, '25May 26, '26Nov 20, '26
  • IMVT +36.2%
  • CYTK -24.4%

Head to head

MetricIMVTCYTK
Price$31.77$50.78
Change today▼ 2.31%▼ 1.32%
Market cap$6.57B$7.07B
Return, 3 months-26.7%-34.1%
Return, year to date+25.0%-20.1%
Return, 1 year+40.6%-22.4%
P/E (TTM)––
P/B10.0-22.0
P/E percentile vs own 5y28th65th
Dividend yield––
Revenue growth (YoY, latest qtr)–+2,356.5%
Net profit growth (YoY)+23.1%+37.9%
Gross margin–95.3%
Operating margin–-625.2%
Net margin–-686.6%
Return on equity-86.5%–
Analyst target vs. price+52.4%+111.3%
Analyst buy share75%94%
RSI (14)4830
30-day volatility62.7%52.6%
Max drawdown, 1 year-40.5%-41.8%
Trend readLeaning bearishStrong downtrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • CYTK is the largest of the group by market value.
  • IMVT has returned the most over the past year.
  • CYTK has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top